194 related articles for article (PubMed ID: 37131100)
1. Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy.
Jansen FM; Smits LJT; Thomas PWA; de Jong DJ; Kreijne JE; van Dop WA; den Broeder N; Hoentjen F
Dig Dis Sci; 2023 Jul; 68(7):2936-2945. PubMed ID: 37131100
[TBL] [Abstract][Full Text] [Related]
2. Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment.
Kreijne JE; de Veer RC; de Boer NK; Dijkstra G; West R; Moorsel SAW; de Jong DJ; van der Woude CJ; de Vries AC;
Aliment Pharmacol Ther; 2019 Aug; 50(4):407-415. PubMed ID: 31359480
[TBL] [Abstract][Full Text] [Related]
3. Limited added value of laboratory monitoring in thiopurine maintenance monotherapy in inflammatory bowel disease patients.
Kreijne JE; de Vries AC; de Veer RC; Bouma G; Dijkstra G; Voskuil MD; West R; van Moorsel SAW; de Jong DJ; de Boer NK; van der Woude CJ;
Aliment Pharmacol Ther; 2020 Jun; 51(12):1353-1364. PubMed ID: 32342997
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.
Bayoumy AB; van Liere ELSA; Simsek M; Warner B; Loganayagam A; Sanderson JD; Anderson S; Nolan J; de Boer NK; Mulder CJJ; Ansari A
BMC Gastroenterol; 2020 Sep; 20(1):296. PubMed ID: 32917155
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of thiopurine-related adverse events in elderly patients with IBD.
Calafat M; Mañosa M; Cañete F; Ricart E; Iglesias E; Calvo M; Rodríguez-Moranta F; Taxonera C; Nos P; Mesonero F; Martín-Arranz MD; Mínguez M; Gisbert JP; García-López S; de Francisco R; Gomollón F; Calvet X; Garcia-Planella E; Rivero M; Martínez-Cadilla J; Argüelles F; Arias L; Cimavilla M; Zabana Y; Domènech E;
Aliment Pharmacol Ther; 2019 Oct; 50(7):780-788. PubMed ID: 31429097
[TBL] [Abstract][Full Text] [Related]
6. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
Kreijne JE; Seinen ML; Wilhelm AJ; Bouma G; Mulder CJ; van Bodegraven AA; de Boer NK
Ther Drug Monit; 2015 Dec; 37(6):797-804. PubMed ID: 25853923
[TBL] [Abstract][Full Text] [Related]
7. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.
Teml A; Schaeffeler E; Herrlinger KR; Klotz U; Schwab M
Clin Pharmacokinet; 2007; 46(3):187-208. PubMed ID: 17328579
[TBL] [Abstract][Full Text] [Related]
8. Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience.
Macaluso FS; Renna S; Maida M; Dimarco M; Sapienza C; Affronti M; Orlando E; Rizzuto G; Orlando R; Ventimiglia M; Cottone M; Orlando A
Scand J Gastroenterol; 2017 Sep; 52(9):981-987. PubMed ID: 28554266
[TBL] [Abstract][Full Text] [Related]
9. Minimal risk of lymphoma and non-melanoma skin cancer despite long-term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India.
Ranjan MK; Kante B; Vuyyuru SK; Kumar P; Mundhra SK; Golla R; Sharma R; Sahni P; Das P; Makharia G; Kedia S; Ahuja V
J Gastroenterol Hepatol; 2022 Aug; 37(8):1544-1553. PubMed ID: 35501287
[TBL] [Abstract][Full Text] [Related]
10. Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study.
Jagt JZ; Pothof CD; Buiter HJC; van Limbergen JE; van Wijk MP; Benninga MA; de Boer NKH; de Meij TGJ
Dig Dis Sci; 2022 Jan; 67(1):241-251. PubMed ID: 33532972
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease.
Ansari A; Elliott T; Baburajan B; Mayhead P; O'Donohue J; Chocair P; Sanderson J; Duley J
Aliment Pharmacol Ther; 2008 Sep; 28(6):734-41. PubMed ID: 19145729
[TBL] [Abstract][Full Text] [Related]
12. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
van Asseldonk DP; Seinen ML; de Boer NK; van Bodegraven AA; Mulder CJ
J Crohns Colitis; 2012 Feb; 6(1):95-101. PubMed ID: 22261533
[TBL] [Abstract][Full Text] [Related]
13. The drug-survival of low-dose thioguanine in patients with inflammatory bowel disease: a retrospective observational study.
Gensmyr-Singer H; Werner M; Karling P
Therap Adv Gastroenterol; 2024; 17():17562848241228064. PubMed ID: 38384282
[TBL] [Abstract][Full Text] [Related]
14. Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease.
Vasudevan A; Beswick L; Friedman AB; Moltzen A; Haridy J; Raghunath A; Sparrow M; van Langenberg D
Dig Liver Dis; 2018 Jul; 50(7):682-688. PubMed ID: 29525182
[TBL] [Abstract][Full Text] [Related]
15. Safety of thiopurines in the treatment of inflammatory bowel disease.
de Jong DJ; Derijks LJ; Naber AH; Hooymans PM; Mulder CJ
Scand J Gastroenterol Suppl; 2003; (239):69-72. PubMed ID: 14743886
[TBL] [Abstract][Full Text] [Related]
16. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.
Leong RW; Gearry RB; Sparrow MP
Expert Opin Drug Saf; 2008 Sep; 7(5):607-16. PubMed ID: 18759713
[TBL] [Abstract][Full Text] [Related]
17. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients.
Chaparro M; Ordás I; Cabré E; Garcia-Sanchez V; Bastida G; Peñalva M; Gomollón F; García-Planella E; Merino O; Gutiérrez A; Esteve M; Márquez L; Garcia-Sepulcre M; Hinojosa J; Vera I; Muñoz F; Mendoza JL; Cabriada JL; Montoro MA; Barreiro-de Acosta M; Ceña G; Saro C; Aldeguer X; Barrio J; Maté J; Gisbert JP
Inflamm Bowel Dis; 2013 Jun; 19(7):1404-10. PubMed ID: 23665964
[TBL] [Abstract][Full Text] [Related]
18. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
Gómez-García M; Cabello-Tapia MJ; Sánchez-Capilla AD; De Teresa-Galván J; Redondo-Cerezo E
World J Gastroenterol; 2013 Aug; 19(30):4877-86. PubMed ID: 23946592
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
Spencer E; Norris E; Williams C; Dubinsky MC
Inflamm Bowel Dis; 2019 Jan; 25(1):142-149. PubMed ID: 29920603
[TBL] [Abstract][Full Text] [Related]
20. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
Dubinsky MC; Feldman EJ; Abreu MT; Targan SR; Vasiliauskas EA
Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
